Home A sensitive chemiluminescence imaging immunoassay for simultaneous detection of serum oxidized lipoprotein(a) and low density lipoprotein
Article
Licensed
Unlicensed Requires Authentication

A sensitive chemiluminescence imaging immunoassay for simultaneous detection of serum oxidized lipoprotein(a) and low density lipoprotein

  • Ruijie Yu , Jiaxi Song , Jia Wu , Dongmei Niu , Lijuan Ma , Chen Zong , Huangxian Ju EMAIL logo and Junjun Wang EMAIL logo
Published/Copyright: January 14, 2014
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 52 Issue 6

Abstract

Background: Oxidized lipoprotein(a) [ox-Lp(a)] and oxidized low density lipoprotein (ox-LDL) levels have been reported to be useful predictors of cardiovascular events. The study developed a chemiluminescence (CL) imaging immunoassay method for simultaneously detecting serum concentrations of ox-Lp(a) and ox-LDL.

Methods: Ox-Lp(a) and ox-LDL levels were measured by CL imaging immunoassay using a disposable immunosensor array as the carrier and a charge-coupled device as the detector, and were studied in 46 acute coronary syndromes (ACS) patients, 58 stable coronary artery disease (CAD) and 61 control subjects.

Results: This method showed good linear relations (R2>0.99) in the concentration range of 2.00×10–5–2.00×10–1 and 2.40×10–4–2.40 U/mL for ox-Lp(a) and ox-LDL, respectively. The detection limits for ox-Lp(a) and ox-LDL were 2.40×10–6 and 3.00×10–5 U/mL, respectively. The intra- and inter-assay coefficients of variation (CV) were 4.90%–6.76% and 7.11%–10.06% for ox-Lp(a), and 5.01%–6.04% and 5.47%–9.77% for ox-LDL, respectively. The mean recovery was 99.31% for ox-Lp(a) and 99.57% for ox-LDL, respectively. Significant correlations were observed between ox-Lp(a) levels detected by CL imaging immunoassay and ELISA, and between ox-LDL levels detected by the two methods, respectively. Furthermore, ox-Lp(a) and ox-LDL levels increased in stable CAD, and especially in ACS.

Conclusions: The CL imaging immunoassay provided a simple, sensitive and reliable method for the simultaneous determination of serum ox-Lp(a) and ox-LDL. The clinical monitoring ox-Lp(a) and ox-LDL levels may possess distinctly clinical value for assessment of CAD risk.

Keywords: chemiluminescence imaging; coronary artery disease; immunoassay; lipoprotein(a); low density lipoprotein; oxidation
Corresponding authors: Junjun Wang, Department of Clinical Laboratory, Clinical School of Medicine, Nanjing University, Jinling Hospital, #305 East Zhongshan Road, Nanjing 210002, P.R. China, Phone: +86 25 84815775, Fax: +86 25 84815775, E-mail: ; and Huangxian Ju, State Key Laboratory of Analytical Chemistry for Life Science, Department of Chemistry, Nanjing University, Nanjing 210093, P.R. China, Phone: +86 25 83593593, Fax: +86 25 83593593, E-mail:
aRuijie Yu and Jiaxi Song contributed equally to this work.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (NSFC 81271904) and the Special-funded Program on National Key Scientific Instruments and Equipment Development of China (2012YQ 03026109).

Conflict of interest statement

Authors’ conflict of interest disclosure: The authors have no conflicts of interest regarding the publication of this article. Research support played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

References

1. Scanu AM, Lawn RM, Berg K. Lipoprotein (a) and atherosclerosis. Ann Intern Med 1991;115:209–18.10.7326/0003-4819-115-3-209Search in Google Scholar

2. Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995;91:948–50.10.1161/01.CIR.91.4.948Search in Google Scholar

3. Zhuang Y, Li J, Wang J. Apolipoprotein(a) phenotypes in cardio-cerebrovascular diseases. Chem Phys Lipids 1994; 67–68:293–7.10.1016/0009-3084(94)90149-XSearch in Google Scholar

4. Podrez EA, O′Neil J, Salomon RG, Schreiber MJ, Hoff HF. Measurement of oxidation in plasma Lp(a) in CAPD patients using a novel ELISA. Kidney Int 1998;54:637–45.10.1046/j.1523-1755.1998.00034.xSearch in Google Scholar

5. Naruszewicze M, Giroux LM, Davignon J. Oxidative modification of Lp(a) causes changes in the structure and biological properties of apo(a). Chem Phys Lipids 1994;67–68:167–74.10.1016/0009-3084(94)90136-8Search in Google Scholar

6. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992;267:4143–51.10.1016/S0021-9258(19)50640-8Search in Google Scholar

7. Gillotte-Taylor K, Boullier A, Witztum JL, Steinberg D, Quehenberger O. Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. J Lipid Res 2001;42:1474–82.10.1016/S0022-2275(20)30281-9Search in Google Scholar

8. Ragab MS, Selvaraj P, Sgoutas DS. Oxidized lipoprotein (a) induces cell adhesion molecule Mac-1 (CD 11b) and enhances adhesion of the monocytic cell line U937 to cultured endothelial cells. Atherosclerosis 1996;123:103–13.10.1016/0021-9150(95)05790-0Search in Google Scholar

9. Ma FX, Zhou B, Chen Z, Ren Q, Lu SH, Sawamura T, et al. Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial nitric oxide synthase. J Lipid Res 2006;47:1227–37.10.1194/jlr.M500507-JLR200Search in Google Scholar PubMed

10. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:844–8.10.1161/01.ATV.21.5.844Search in Google Scholar

11. Segev A, Strauss BH, Witztum JL, Lau HK, Tsimikas S. Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. Am Heart J 2005;150:1007–14.10.1016/j.ahj.2004.12.008Search in Google Scholar PubMed

12. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005;112:651–7.10.1161/CIRCULATIONAHA.104.529297Search in Google Scholar PubMed

13. Johnston N, Jernberg T, Lagerqvist B, Siegbahn A, Wallentin L. Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease. Int J Cardiol 2006;113:167–73.10.1016/j.ijcard.2005.11.006Search in Google Scholar PubMed

14. Wang J, Niu D, Meng Y, Han A, Li K, Zhang C. Plasma oxidized lipoprotein(a) and its immune complexes are present in newborns and children. Clin Chim Acta 2009;407:1–5.10.1016/j.cca.2009.06.020Search in Google Scholar PubMed

15. Wang J, Hu B, Kong L, Cai H, Zhang C. Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis: plasma concentrations and relationship to inflammation. Clin Chim Acta 2008;390:67–71.10.1016/j.cca.2007.12.015Search in Google Scholar PubMed

16. Wang JJ, Zhang CN, Meng Y, Han AZ, Gong JB, Li K. Elevated concentrations of oxidized lipoprotein(a) are associated with the presence and severity of acute coronary syndromes. Clin Chim Acta 2009;408:79–82.10.1016/j.cca.2009.07.013Search in Google Scholar PubMed

17. Wang JJ, Han AZ, Meng Y, Gong JB, Zhang CN, Li K, et al. Measurement of oxidized lipoprotein (a) in patients with acute coronary syndromes and stable coronary artery disease by 2 ELISAs: using different capture antibody against oxidized lipoprotein (a) or oxidized LDL. Clin Biochem 2010;43:571–5.10.1016/j.clinbiochem.2009.12.017Search in Google Scholar PubMed

18. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 1996;76:663–9.10.1055/s-0038-1650639Search in Google Scholar

19. Itabe H. Oxidized low-density lipoprotein as a biomarker of in vivo oxidative stress: from atherosclerosis to periodontitis. J Clin Biochem Nutr 2012;51:1–8.10.3164/jcbn.11-00020R1Search in Google Scholar PubMed PubMed Central

20. Fefer P, Tsimikas S, Segev A, Sparkes J, Otsuma F, Kolodgie F, et al. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. Cardiovasc Revasc Med 2012;13:11–9.10.1016/j.carrev.2011.08.001Search in Google Scholar PubMed

21. Kotani K, Yamada S, Yamada T, Taniguchi N, Sakurabayashi I. The relationship between oxidized lipoprotein(a) and carotid atherosclerosis in asymptomatic subjects: a comparison with native lipoprotein(a). Lipids Health Dis 2011;10:174.10.1186/1476-511X-10-174Search in Google Scholar PubMed PubMed Central

22. Wang J, Zhang C, Gong J, Zhu Y, Fu L, Wang X, et al. Development of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a) by using purified human oxidized lipoprotein(a) autoantibodies as capture antibody. Clin Chim Acta 2007;385:73–8.10.1016/j.cca.2007.06.023Search in Google Scholar PubMed

23. Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 2004;109:3164–70.10.1161/01.CIR.0000130844.01174.55Search in Google Scholar PubMed

24. Yu FY, Gribas AV, Vdovenko MM, Sakharov IY. Development of ultrasensitive direct chemiluminescent enzyme immunoassay for determination of aflatoxin B1 in food products. Talanta 2013;107:25–9.10.1016/j.talanta.2012.12.047Search in Google Scholar PubMed

25. Dai H, Zhu J, Yang Z, Li J, Jiao Xa, Hu X, et al. A paramagnetic microspheres based automation-friendly rapid chemiluminescent immunoassay method for sensitive detection of chicken interferon-gamma. Chem Comm 2013;49:1708–10.10.1039/c3cc38040hSearch in Google Scholar PubMed

26. Yang Z, Zong C, Yan F, Ju H. Automated chemiluminescent dual-analyte immunoassay based on resolved immunosensing channels. Talanta 2010;82:1462–7.10.1016/j.talanta.2010.07.018Search in Google Scholar PubMed

27. Zong C, Wu J, Wang C, Ju H, Yan F. Chemiluminescence imaging immunoassay of multiple tumor markers for cancer screening. Anal Chem 2012;84:2410–5.10.1021/ac203179gSearch in Google Scholar PubMed

28. FitzGerald SP, Lamont JV, McConnell RI, Benchikh EO. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem 2005;51: 1165–76.10.1373/clinchem.2005.049429Search in Google Scholar PubMed

29. Karsunke XY, Niessner R, Seidel M. Development of a multichannel flow-through chemiluminescence microarray chip for parallel calibration and detection of pathogenic bacteria. Anal Bioanal Chem 2009;395:1623–30.10.1007/s00216-009-2905-7Search in Google Scholar PubMed

30. Zong C, Wu J, Xu J, Ju H, Yan F. Multilayer hemin/G-quadruplex wrapped gold nanoparticles as tag for ultrasensitive multiplex immunoassay by chemiluminescence imaging. Biosens Bioelectron 2013;43:372–8.10.1016/j.bios.2012.12.051Search in Google Scholar PubMed

31. Wang JJ, Liu XZ, Zhuang YY, Li LY. Correlation between susceptibility of LDL subfractions to in vitro oxidation and in vivo oxidized LDL. Clin Biochem 2000;33:71–3.10.1016/S0009-9120(99)00065-XSearch in Google Scholar

32. Wang J, Gu Q, Li K, Zhang C. CETP and oxidized LDL levels increase in dyslipidemic subjects. Clin Biochem 2007;40: 995–9.10.1016/j.clinbiochem.2007.05.010Search in Google Scholar PubMed

33. Winyard PG, Tatzber F, Esterbauer H, Kus ML, Blake DR, Morris CJ. Presence of foam cells containing oxidised low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 1993;52:677–80.10.1136/ard.52.9.677Search in Google Scholar PubMed PubMed Central

34. Wang J, Zhang C, Han A, Gong J, Li K. Percutaneous coronary intervention results in acute increases in native and oxidized lipoprotein (a) in patients with acute coronary syndrome and stable coronary artery disease. Clin Biochem 2010;43:1107–11.10.1016/j.clinbiochem.2010.06.019Search in Google Scholar PubMed

Received: 2013-9-19
Accepted: 2013-12-17
Published Online: 2014-1-14
Published in Print: 2014-6-1

©2014 by Walter de Gruyter Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Quo vadis, biomarkers?
  4. Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research
  5. Reviews
  6. Tracing a roadmap for vitamin B12 testing using the health technology assessment approach
  7. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide 2 antibody and anti-cyclic citrullinated peptide 3 antibody in rheumatoid arthritis
  8. Perspectives
  9. Present and future of cancer biomarkers
  10. Opinion Paper
  11. A repository for “rare” tumor markers?
  12. Genetics and Molecular Diagnostics
  13. Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP450 Test® no-call in the clinical setting
  14. General Clinical Chemistry and Laboratory Medicine
  15. Tighter precision target required for lactate testing in patients with lactic acidosis
  16. The revised Lund-Malmö GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population
  17. Validation of a point-of-care (POC) lactate testing device for fetal scalp blood sampling during labor: clinical considerations, practicalities and realities
  18. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests
  19. Evaluation of clinical cases in External Quality Assessment Scheme (EQAS) for the urinary sediment
  20. N Latex FLC serum free light-chain assays in patients with renal impairment
  21. A new high-sensitive nephelometric method for assaying serum C-reactive protein based on phosphocholine interaction
  22. A sensitive chemiluminescence imaging immunoassay for simultaneous detection of serum oxidized lipoprotein(a) and low density lipoprotein
  23. Quantification of teicoplanin in plasma by LC-MS with online sample clean-up and comparison with QMS® assay
  24. Cancer Diagnostics
  25. An epidemiology-based model to estimate the rate of inappropriateness of tumor marker requests
  26. Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma
  27. Cardiovascular Diseases
  28. The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature
  29. Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments
  30. Infectious Diseases
  31. Serum miR-122 levels are related to coagulation disorders in sepsis patients
  32. Letter to the Editors
  33. Effect of storage conditions and freeze/thaw cycles on serum and plasma levels of anti-acetylcholine receptor (AChR) antibody
  34. Enzymatic isotope dilution mass spectrometry (IDMS) traceable serum creatinine is preferable over Jaffe in neonates and young infants
  35. Vitamin D, atopy, immunity
  36. 25-Hydroxy vitamin D levels in chronic urticaria and its correlation with disease severity from a tertiary care centre in South India
  37. High prevalence of anti-thyroid antibodies associated with a low vitamin D status in a pediatric cohort
  38. Serum melatonin levels in psoriasis and associated depressive symptoms
  39. Congress Abstracts
  40. ISMD2014 Tenth International Symposium on Molecular Diagnostics
https://doi.org/10.1515/cclm-2013-0786
Keywords for this article
chemiluminescence imaging; coronary artery disease; immunoassay; lipoprotein(a); low density lipoprotein; oxidation

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Quo vadis, biomarkers?
  4. Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research
  5. Reviews
  6. Tracing a roadmap for vitamin B12 testing using the health technology assessment approach
  7. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide 2 antibody and anti-cyclic citrullinated peptide 3 antibody in rheumatoid arthritis
  8. Perspectives
  9. Present and future of cancer biomarkers
  10. Opinion Paper
  11. A repository for “rare” tumor markers?
  12. Genetics and Molecular Diagnostics
  13. Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP450 Test® no-call in the clinical setting
  14. General Clinical Chemistry and Laboratory Medicine
  15. Tighter precision target required for lactate testing in patients with lactic acidosis
  16. The revised Lund-Malmö GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population
  17. Validation of a point-of-care (POC) lactate testing device for fetal scalp blood sampling during labor: clinical considerations, practicalities and realities
  18. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests
  19. Evaluation of clinical cases in External Quality Assessment Scheme (EQAS) for the urinary sediment
  20. N Latex FLC serum free light-chain assays in patients with renal impairment
  21. A new high-sensitive nephelometric method for assaying serum C-reactive protein based on phosphocholine interaction
  22. A sensitive chemiluminescence imaging immunoassay for simultaneous detection of serum oxidized lipoprotein(a) and low density lipoprotein
  23. Quantification of teicoplanin in plasma by LC-MS with online sample clean-up and comparison with QMS® assay
  24. Cancer Diagnostics
  25. An epidemiology-based model to estimate the rate of inappropriateness of tumor marker requests
  26. Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma
  27. Cardiovascular Diseases
  28. The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature
  29. Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments
  30. Infectious Diseases
  31. Serum miR-122 levels are related to coagulation disorders in sepsis patients
  32. Letter to the Editors
  33. Effect of storage conditions and freeze/thaw cycles on serum and plasma levels of anti-acetylcholine receptor (AChR) antibody
  34. Enzymatic isotope dilution mass spectrometry (IDMS) traceable serum creatinine is preferable over Jaffe in neonates and young infants
  35. Vitamin D, atopy, immunity
  36. 25-Hydroxy vitamin D levels in chronic urticaria and its correlation with disease severity from a tertiary care centre in South India
  37. High prevalence of anti-thyroid antibodies associated with a low vitamin D status in a pediatric cohort
  38. Serum melatonin levels in psoriasis and associated depressive symptoms
  39. Congress Abstracts
  40. ISMD2014 Tenth International Symposium on Molecular Diagnostics
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 5.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2013-0786/html
Scroll to top button